Device type · NDW
Assay, Porphyrin, Spectrophotometry, Lithium
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
NDW
Clinical Toxicology
Device class
Class II
FDA decisions since 2015
1
510(k), De Novo and PMA
Adverse event reports
1
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Assay, Porphyrin, Spectrophotometry, Lithium
- Product code
- NDW
- Device class
- Class II
- Review panel
- Clinical Toxicology
- Regulation
- 21 CFR 862.3560
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for NDW
Latest FDA decisions
K243462 · Decided Aug 1, 2025 · 266 days after receipt
Device type: Assay, Porphyrin, Spectrophotometry, Lithium (NDW) · Laboratory Medicine & Pathology
Reports received
1
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
1
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 1 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 1 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 1 | 0 | 0 | 0 |
| Oct 25 | 1 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 1 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- High Test Results1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions1
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Atellica CH Lithium_2 (LITH_2), Siemens Material Number 11532401. in vitro diagnostic assayOpen, Classified
Siemens Healthcare Diagnostics, Inc.
Z-0104-2023 · Started Sep 19, 2022 · Posted by FDA Oct 20, 2022
Reason given: Potential for falsely elevated LITH_2 and Li results on the Atellica CH 930 Analyzer. In the worst case, there is a potential for erroneously elevated lithium patient results, which may lead to inappropriate dosage adjustment, potentially affecting treatment efficacy.
Cause as FDA categorized it: Under Investigation by firm
- Atellica CH Lithium (Li), Siemens Material Number 11097535. in vitro diagnostic assayOpen, Classified
Siemens Healthcare Diagnostics, Inc.
Z-0105-2023 · Started Sep 19, 2022 · Posted by FDA Oct 20, 2022
Reason given: Potential for falsely elevated LITH_2 and Li results on the Atellica CH 930 Analyzer. In the worst case, there is a potential for erroneously elevated lithium patient results, which may lead to inappropriate dosage adjustment, potentially affecting treatment efficacy.
Cause as FDA categorized it: Under Investigation by firm
- Atellica CH Lithium_2 (LITH_2), Siemens Material Number 11097637Open, Classified
Siemens Healthcare Diagnostics, Inc.
Z-0931-2022 · Started Feb 9, 2022
Reason given: Siemens Healthcare Diagnostics Inc. has confirmed the potential for reagent carryover impacting quality control (QC), patient samples, and calibrator results.
Cause as FDA categorized it: Device Design
- ADVIA Chemistry CalibratorTerminated
Siemens Healthcare Diagnostics, Inc.
Z-2430-2020 · Started Jun 5, 2020
Reason given: Calibration errors have been observed with the Total and Direct Bilirubin assays when using Chemistry Calibrator lot 534177 for ADVIA Chemistry and lot 534179 for Atellica CH.
Cause as FDA categorized it: Nonconforming Material/Component
Z-2551-2019 · Started Jun 28, 2019
Reason given: Added an additional SmartWash parameter for the Lithium and Alinity c Lithium Reagent Kit, catalogue number 8L25-30 and 08P5320 to prevent the potential for carryover from the ARCHITECT Lactate Dehydrogenase (LDH) reagent (LN 2P56) may result infalsely elevated lithium patient results
Cause as FDA categorized it: Under Investigation by firm
Z-2552-2019 · Started Jun 28, 2019
Reason given: Added an additional SmartWash parameter for the Lithium and Alinity c Lithium Reagent Kit, catalogue number 8L25-30 and 08P5320 to prevent the potential for carryover from the ARCHITECT Lactate Dehydrogenase (LDH) reagent (LN 2P56) may result infalsely elevated lithium patient results
Cause as FDA categorized it: Under Investigation by firm
Z-1440-06 · Started May 15, 2006 · Posted by FDA Aug 26, 2006
Reason given: Incorrect Reagent Status-When a new cartridge of Infinity Lithium Reagent is loaded on to the UniCel DxC System, the Reagent Status screen will incorrectly show 'Days Left' as 21. The correct Reagent Status for a new Lithium reagent cartridge is 14 days. Lithium reagent used past 14 days may produce low quality...
Cause as FDA categorized it: Other
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.